Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZILSARTAN MEDOXOMIL vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Treatment of hypertension (FDA-approved),Off-label: heart failure, diabetic nephropathy
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
40 mg orally once daily. May increase to 80 mg once daily if needed.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes esterase-mediated hydrolysis to azilsartan.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged)
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
High (>99%) to serum albumin.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Vd of about 16 L (0.23 L/kg for a 70 kg individual); indicates limited extravascular distribution.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral bioavailability approximately 60% under fed conditions (food reduces absorption); absolute bioavailability not determined in humans.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
No dose adjustment required for GFR ≥15 m L/min/1.73 m². Not recommended for GFR <15 m L/min/1.73 m² due to lack of data.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Not approved for use in pediatric patients (safety and efficacy not established).
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
No specific dose adjustment recommended; initiate at 40 mg once daily. Monitor renal function and blood pressure carefully due to increased sensitivity.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
none
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Fetal toxicity: avoid use in pregnancy,Hypotension in volume-depleted patients,Renal impairment: monitor renal function,Hyperkalemia: monitor potassium levels
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Pregnancy (second and third trimesters),Concomitant use with aliskiren in patients with diabetes or renal impairment (e GFR <60 m L/min)
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
No significant food interactions; can be taken with or without food. Avoid excessive potassium intake from high-potassium foods (e.g., bananas, oranges, spinach, potatoes) or potassium-containing salt substitutes. Limit alcohol intake as it may increase blood pressure or cause dizziness.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal anuria, hypotension, and death.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
No data on presence in human milk. Manufacturer recommends discontinuing breastfeeding or drug due to potential risk. M/P ratio unknown.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No dose adjustments during pregnancy; however, use is contraindicated in second and third trimesters due to fetal toxicity. If exposure occurs, discontinue as soon as possible.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Azilsartan medoxomil has the highest affinity for AT1 receptors among ARBs; may cause a rapid decrease in blood pressure in volume-depleted patients; avoid use in pregnancy (Category D); monitor renal function and serum potassium; less CYP450 interaction potential than losartan or irbesartan; can be taken without regard to meals; dose adjustment not required in mild-to-moderate hepatic impairment.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take once daily at the same time each day with or without food.,Avoid becoming dehydrated; drink adequate fluids unless directed otherwise.,Do not use if pregnant or planning to become pregnant; notify your doctor immediately if pregnancy occurs.,Do not take with aliskiren if you have diabetes or renal impairment.,Report any signs of angioedema (swelling of face, lips, tongue, difficulty breathing) or severe dizziness.,May cause dizziness, especially during first few days; avoid driving until you know how the medication affects you.,Avoid potassium supplements and salt substitutes containing potassium unless approved by your doctor.,Do not stop taking the medication without talking to your doctor.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
"The combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), can lead to a significant reduction in the antihypertensive and cardioprotective effects of azilsartan. NSAIDs inhibit cyclooxygenase enzymes, reducing prostaglandin synthesis, which diminishes the vasodilatory and natriuretic actions that support blood pressure control mediated by ARBs. This interaction may result in loss of blood pressure control, increased risk of renal impairment (especially in volume-depleted or elderly patients), and potential antagonism of the renal protective effects of ARBs in conditions like heart failure or chronic kidney disease."
"Oxprenolol, a non-selective beta-blocker, may attenuate the compensatory sympathetic response to Azilsartan medoxomil-induced hypotension, potentially leading to an excessive drop in blood pressure. This combination can also result in reduced cardiac output due to additive negative chronotropic effects, increasing the risk of bradycardia and heart block. Clinically, patients may experience severe hypotension, dizziness, syncope, or exacerbated heart failure symptoms."
"The combination of timolol, a non-selective beta-blocker, with azilsartan medoxomil, an angiotensin II receptor blocker (ARB), may lead to an increased risk of hypotension, bradycardia, and additive antihypertensive effects. Timolol can antagonize the compensatory sympathetic response to azilsartan-induced vasodilation, potentially resulting in excessive blood pressure reduction. Additionally, both drugs can affect renal perfusion, raising the risk of renal impairment in susceptible patients."
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZILSARTAN MEDOXOMIL vs ALFENTA, answered by our medical review team.
AZILSARTAN MEDOXOMIL is a Angiotensin II Receptor Blocker that works by Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZILSARTAN MEDOXOMIL and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZILSARTAN MEDOXOMIL is: 40 mg orally once daily. May increase to 80 mg once daily if needed.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZILSARTAN MEDOXOMIL and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZILSARTAN MEDOXOMIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligo. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.